Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SpyGlass PharmaSGP -0.59%12 Current Ratio is 25.06 as of Jun. 2026, which is 38% above its 10-year median of 18.11. GuruFocus rates SGP with a GF Score™ of 12/100. Among 1,405 Biotechnology companies, SpyGlass Pharma ranks better than 97.72% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. SpyGlass Pharma's current ratio for the quarter that ended in Jun. 2026 was 25.06.
SpyGlass Pharma has a current ratio of 25.06. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for SpyGlass Pharma's Current Ratio or its related term are showing as below:
SGP'
s Current Ratio Range Over the Past 10 Years
Min: 2.23 Med: 18.11 Max: 38
Current: 38
During the past 3 years, SpyGlass Pharma's highest Current Ratio was 38.00. The lowest was 2.23. And the median was 18.11.
SGP's Current Ratio is ranked better than 97.72% of 1405
companies
in the Biotechnology industry
Industry Median: 3.83
vs SGP: 38.00
SpyGlass Pharma (NAS:SGP) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
SpyGlass Pharma Current Ratio Related Terms
SpyGlass Pharma Current Ratio Historical Data
* Premium members only.
The historical data trend for SpyGlass Pharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SpyGlass Pharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SpyGlass Pharma Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SpyGlass Pharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where SpyGlass Pharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SpyGlass Pharma (SGP) has a Current Ratio of 25.06 as of Jun. 2026. This is 38% above median its historical median of 18.11. Over the past decade, SpyGlass Pharma's Current Ratio has ranged from 2.23 to 38.00. According to the industry distribution chart, SpyGlass Pharma ranks #32 out of 1405 companies in the Biotechnology industry, placing it in the top 2.3%.
Is SpyGlass Pharma's Current Ratio too high?
SpyGlass Pharma's current Current Ratio of 25.06 is 38% above median its 10-year median of 18.11. Over the past 10 years, this metric has ranged from a low of 2.23 to a high of 38.00. The Biotechnology industry median Current Ratio is 3.83. SpyGlass Pharma's value of 25.06 is 554.3% above this industry median. Based on the distribution chart, SpyGlass Pharma ranks #32 out of 1405 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SpyGlass Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SpyGlass Pharma's Current Ratio compare to RIGL and NGNE?
According to the Biotechnology industry distribution chart, SpyGlass Pharma ranks #32 out of 1405 companies for Current Ratio. This places SpyGlass Pharma in the top 2% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.83. SpyGlass Pharma's value of 25.06 is 554.3% above this benchmark. Historically, SpyGlass Pharma's own Current Ratio has ranged from 2.23 to 38.00 over the past decade. While the company's 10-year median is 18.11 vs. the industry median of 3.83, SpyGlass Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.83, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SpyGlass Pharma's current Current Ratio of 25.06 is 554.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SpyGlass Pharma's current Current Ratio is 25.06, which is 38% above median its own 10-year median of 18.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SpyGlass Pharma stock overvalued right now?
SpyGlass Pharma (SGP) has a current Current Ratio of 25.06. The current Current Ratio is 25.06, which is 38% above median its 10-year median of 18.11 and 554.3% above the Biotechnology industry median of 3.83. SpyGlass Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For SpyGlass Pharma (SGP), the current Current Ratio is 25.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
12GF Score
Get the complete analysis for SGP
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGP has been successfully added to your 
